NCT00522015

Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST 4. changes in motor activity are associated with changes in language and overall results of the in MMST

Conditions

• Progressive Supranuclear Palsy
• Dementia

Interventions

Type	Name	Description
DRUG	rivastigmine	rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-12-01
• Completion: 2010-02-01
• First posted: 2007-08-29
• Last updated: 2008-02-18

Locations

1 site across 1 country: Germany